日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner

PD-L1/4-1BB 双特异性抗体-Anticalin 融合蛋白 PRS-344/S095012 以肿瘤局部方式引发强烈的 T 细胞刺激

Janet K Peper-Gabriel, Marina Pavlidou, Lucia Pattarini, Aizea Morales-Kastresana, Thomas J Jaquin, Catherine Gallou, Eva-Maria Hansbauer, Marleen Richter, Helene Lelievre, Alix Scholer-Dahirel, Birgit Bossenmaier, Celine Sancerne, Matthieu Riviere, Maximilien Grandclaudon, Markus Zettl, Rachida S B

DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity

DuoMab:一种基于 CrossMab 的新型 IgG 衍生抗体形式,可增强抗体依赖性细胞介导的细胞毒性

Claudio Sustmann, Steffen Dickopf, Jörg T Regula, Hubert Kettenberger, Michael Mølhøj, Christian Gassner, Diana Weininger, Sebastian Fenn, Tobias Manigold, Lothar Kling, Klaus-Peter Künkele, Manfred Schwaiger, Birgit Bossenmaier, Julia J Griese, Karl-Peter Hopfner, Alexandra Graff-Meyer, Henning Sta

Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity

将针对间皮素的局部免疫毒素与 CTLA-4 阻断剂相结合,通过促进抗癌免疫力协同消除小鼠癌症

Yasmin Leshem, James O'Brien, Xiufen Liu, Tapan K Bera, Masaki Terabe, Jay A Berzofsky, Birgit Bossenmaier, Gerhard Niederfellner, Chin-Hsien Tai, Yoram Reiter, Ira Pastan

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer

直接雌激素受体 (ER)/HER 家族串扰介导 ER+ 乳腺癌对鲁瑞珠单抗和帕妥珠单抗的敏感性

Denis Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Max Hasmann, John Crown, Andrés Cervantes, Martin Weisser, Birgit Bossenmaier

Deciphering the stepwise binding mode of HRG1β to HER3 by surface plasmon resonance and interaction map

通过表面等离子体共振和相互作用图解读 HRG1β 与 HER3 的逐步结合模式

Carmen Peess, Leopold von Proff, Sabine Goller, Karl Andersson, Michael Gerg, Magnus Malmqvist, Birgit Bossenmaier, Michael Schräml

Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody

RG7116 的临床前药代动力学、药效学和疗效:一种新型人源化、糖基化工程抗 HER3 抗体

Georgina Meneses-Lorente, Thomas Friess, Irene Kolm, Gabriele Hölzlwimmer, Sabine Bader, Christophe Meille, Marlene Thomas, Birgit Bossenmaier

ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116

以人表皮生长因子受体 3 为靶向抗体 ⁸⁹Zr-RG7116 进行免疫 PET 和生物分布

Anton G T Terwisscha van Scheltinga, Marjolijn N Lub-de Hooge, Keelara Abiraj, Carolien P Schröder, Linda Pot, Birgit Bossenmaier, Marlene Thomas, Gabriele Hölzlwimmer, Thomas Friess, Jos G W Kosterink, Elisabeth G E de Vries

Development of bispecific molecules for the in situ detection of protein-protein interactions and protein phosphorylation

开发用于原位检测蛋白质-蛋白质相互作用和蛋白质磷酸化的双特异性分子

Jan van Dieck, Volker Schmid, Dieter Heindl, Sebastian Dziadek, Michael Schraeml, Michael Gerg, Petra Massoner, Alfred M Engel, Georg Tiefenthaler, Serhat Vural, Simon Stritt, Fabian Tetzlaff, Monika Soukupova, Erhard Kopetzki, Birgit Bossenmaier, Marlene Thomas, Christian Klein, Alfred Mertens, Ast

RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation

RG7116 是一种治疗性抗体,可结合无活性的 HER3 受体,并针对免疫效应子激活进行优化

Christian Mirschberger, Christian B Schiller, Michael Schräml, Nikolaos Dimoudis, Thomas Friess, Christian A Gerdes, Ulrike Reiff, Valeria Lifke, Gabriele Hoelzlwimmer, Irene Kolm, Karl-Peter Hopfner, Gerhard Niederfellner, Birgit Bossenmaier

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab

GA201 (RG7160):一种新型人源化糖工程抗 EGFR 抗体,与西妥昔单抗相比,具有增强的 ADCC 和更优异的体内疗效

Christian A Gerdes, Valeria Gonzalez Nicolini, Sylvia Herter, Erwin van Puijenbroek, Sabine Lang, Michaela Roemmele, Ekkehard Moessner, Olivier Freytag, Thomas Friess, Carola H Ries, Birgit Bossenmaier, Hans Joachim Mueller, Pablo Umaña